Association of Potassium Level at Discharge with Long-Term Mortality in Hospitalized Patients with Heart Failure
暂无分享,去创建一个
Y. Shiraishi | S. Kohsaka | A. Goda | T. Yoshikawa | T. Kohno | Mitsunobu Kitamura | S. Higuchi | Shintaro Nakano | M. Takei | Kyoko Soejima | Yuji Nagatomo | Yusuke Miura
[1] M. Kearney,et al. Reduction of heart failure guideline‐directed medication during hospitalization: prevalence, risk factors, and outcomes , 2022, ESC heart failure.
[2] H. Thiele,et al. Guideline‐directed medical therapy in patients undergoing transcatheter edge‐to‐edge repair for secondary mitral regurgitation , 2022, European journal of heart failure.
[3] G. Filippatos,et al. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter‐defibrillator for primary prevention? , 2022, European journal of heart failure.
[4] C. Specchia,et al. Prognostic significance of serum potassium in patients hospitalized for acute heart failure , 2022, ESC heart failure.
[5] M. Link,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Circulation.
[6] T. N. Harrison,et al. Representativeness of the GALACTIC‐HF Clinical Trial in Patients Having Heart Failure With Reduced Ejection Fraction , 2022, Journal of the American Heart Association.
[7] G. Sinagra,et al. [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.
[8] Y. Shiraishi,et al. Different Impact of Beta-Blockers on Long-Term Mortality in Heart Failure Patients with and without Chronic Obstructive Pulmonary Disease , 2021, Journal of clinical medicine.
[9] J. McMurray,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.
[10] L. Lund,et al. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.
[11] G. Filippatos,et al. Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry , 2020, European journal of heart failure.
[12] K. Fukuda,et al. Prediction of sudden cardiac death in Japanese heart failure patients: international validation of the Seattle Proportional Risk Model. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[13] L. Lund,et al. Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry , 2020, European journal of heart failure.
[14] W. Tay,et al. Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN‐HF registry , 2019, European journal of heart failure.
[15] Mohamed O. Saad,et al. Torsemide versus furosemide after acute decompensated heart failure: a retrospective observational study , 2019, BMC Cardiovascular Disorders.
[16] A. Donato,et al. Influence of abnormal potassium levels on mortality among hospitalized heart failure patients in the US: data from National Inpatient Sample , 2019, Journal of community hospital internal medicine perspectives.
[17] C. Linde,et al. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK , 2019, ESC heart failure.
[18] Akshay S. Desai,et al. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas , 2018, European journal of heart failure.
[19] Y. Izumiya,et al. Serum Potassium and Cardiovascular Events in Heart Failure With Preserved Left Ventricular Ejection Fraction Patients , 2018, American journal of hypertension.
[20] A. Gavazzi,et al. Prevalence and prognostic impact of non‐cardiac co‐morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community‐based study , 2018, European journal of heart failure.
[21] P. Ponikowski,et al. Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT‐CHF , 2018, European journal of heart failure.
[22] M. Metra,et al. Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality , 2017, Circulation.
[23] M. Ochiai,et al. The association between high‐dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure , 2017, ESC heart failure.
[24] L. Køber,et al. Associations of serum potassium levels with mortality in chronic heart failure patients , 2017, European heart journal.
[25] Zhilin Qu,et al. Electrophysiology of Hypokalemia and Hyperkalemia. , 2017, Circulation. Arrhythmia and electrophysiology.
[26] P. Ponikowski,et al. Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). , 2017, The American journal of cardiology.
[27] H. Kasanuki,et al. Etiology of Heart Failure and Outcomes in Patients Hospitalized for Acute Decompensated Heart Failure With Preserved or Reduced Ejection Fraction. , 2016, The American journal of cardiology.
[28] K. Fukuda,et al. Validation of the Get With The Guideline-Heart Failure risk score in Japanese patients and the potential improvement of its discrimination ability by the inclusion of B-type natriuretic peptide level. , 2016, American heart journal.
[29] J. Weiss,et al. Molecular Basis of Hypokalemia-Induced Ventricular Fibrillation , 2015, Circulation.
[30] Eric E. Smith,et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.
[31] Eric E. Smith,et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Journal of the American College of Cardiology.
[32] P. Ponikowski,et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry , 2013, European journal of heart failure.
[33] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[34] Subhash Banerjee,et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. , 2012, The American journal of cardiology.
[35] B. Kaufmann,et al. Clinical and pharmacological investigations of the new saluretic azosemid , 1978, European Journal of Clinical Pharmacology.
[36] B. Palmer. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.
[37] A. Struthers,et al. What is the optimal serum potassium level in cardiovascular patients? , 2004, Journal of the American College of Cardiology.
[38] D. Levy,et al. Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.
[39] R. Tannen. Diuretic-induced hypokalemia. , 1985, Kidney international.